Michael Torok
About Michael Torok
Michael Torok, age 46, was appointed as a non-executive, independent director of Amarin on April 4, 2025. He co-founded and serves as Managing Director of JEC Capital Partners, with prior roles as CFO of Integrated Dynamics Engineering and earlier positions at PwC. He holds a B.S. in Accounting & Finance and a Master’s in Finance from Boston College. He is nominated for re‑election at the May 13, 2025 AGM and, as of the proxy date, is considered independent by the Board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| JEC Capital Partners, LLC | Co‑Founder & Managing Director | 2008–present | Capital allocation, M&A and operational improvement focus as investor/operator . |
| Integrated Dynamics Engineering (acq. by Aalberts) | Chief Financial Officer | 2006–2009 | Led finance through sale to Aalberts Industries (XAMS: AALB) . |
| PricewaterhouseCoopers LLP | Various roles | Early career | Financial services focus . |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Liberated Syndication, Inc. (Libsyn) | Director | Dec 2022–present | Public company board experience . |
| Carisma Therapeutics Inc. (NASDAQ: CARM) | Director | Mar 2023–Oct 2024 | Former public company directorship . |
| Photon Control Inc. (TSX: PHO) | Director | 2016–2018 | Former public company directorship . |
| Symbility Solutions Inc. | Director | 2015–2018 | Former public company directorship . |
| Various (general) | Committee contributions | N/A | Press release notes contributions across audit, compensation, nominating & governance, strategic and pricing committees at past boards . |
Board Governance
- Independence: The Board determined all directors other than the CEO are independent; this includes Mr. Torok as of the April 10, 2025 proxy .
- Committee assignments: On appointment (Apr 4, 2025) he had not been assigned to any committees; committee assignments may be set after the AGM .
- Attendance: The Board held 10 meetings in 2024 and all then‑serving directors met the 75% attendance threshold; Torok was appointed in 2025, so no 2024 attendance record applies to him .
- Board leadership: Independent Chair (Dr. Odysseas Kostas); key committees are fully independent; independent directors hold sessions at every meeting .
- Re‑election: Ordinary resolution to re‑elect Michael Torok at the 2025 AGM (Proposal No. 13) .
Fixed Compensation (Director)
| Component | Amount/Terms | Notes |
|---|---|---|
| Annual Board Retainer (non‑employee director) | $62,500 | Paid quarterly in arrears; proration for partial year . |
| Non‑Executive Chairman Retainer | $95,000 | Not applicable to Torok unless designated Chair . |
| Committee Member Retainers | Audit: $12,000; Remuneration: $10,000; Nominating & Gov: $5,000 | In addition to Board retainer; Torok had no assignments at appointment . |
| Committee Chair Retainers | Audit: $25,000; Remuneration: $20,000; Nominating & Gov: $11,000 | In addition to Board retainer . |
| Retainer settlement election | Cash or unregistered ordinary shares (ADS‑priced or par floor), election window each quarter | Provides alignment option; priced at greater of ADS close +10 days or £0.50 par value . |
Performance Compensation (Director Equity)
| Equity Element | Grant Value/Mix | Vesting | Other Terms |
|---|---|---|---|
| Initial grant for new directors (as revised Feb 2024) | $262,500 total; 75% options / 25% RSUs | Options: 1/3 at yr 1 then quarterly over next 2 yrs; RSUs: annual over 3 yrs | Under 2020 Plan; CIC: director equity fully vests on change of control . |
| Ongoing annual grant | $175,000 total; 75% options / 25% RSUs | Options: annual over 3 yrs; RSUs: annual over 3 yrs | Under 2020 Plan; CIC: director equity fully vests on change of control . |
Structure signals pay‑for‑performance: heavier option weighting (75%) shifts director equity toward stock price outcomes; Amarin reduced director equity sizes and increased option mix in 2023/Jan 2024 to align with market medians .
Other Directorships & Interlocks
| Company | Sector | Role | Potential Interlock/Conflict Relevance |
|---|---|---|---|
| Liberated Syndication, Inc. | Podcasting/Adtech | Director | No disclosed commercial ties to Amarin; governance only . |
| Carisma Therapeutics Inc. | Biotech | Former Director | No disclosed ties to Amarin; tenure ended Oct 2024 . |
| Photon Control Inc. | Semi equipment | Former Director | No disclosed ties to Amarin . |
| Symbility Solutions Inc. | Insurtech | Former Director | No disclosed ties to Amarin . |
The Company reports no related‑party transactions since Jan 1, 2024, and Torok is not party to any Item 404(a) transactions on appointment .
Expertise & Qualifications
- Capital markets, M&A, capital resources, and operational improvements experience (JEC, CFO background) .
- Financial oversight and board experience; contribution across core board committees noted in press release .
- Accounting and finance academic credentials (Boston College) .
Equity Ownership
| Holder (direct/indirect) | Shares | Notes |
|---|---|---|
| Michael Torok – direct | 970,000 | Directly owned as of Apr 4, 2025 . |
| JEC II Associates, LLC (managed by Torok) | 3,000,000 | Indirect beneficial ownership via manager status . |
| The MOS Trust (trustee manager entity managed by Torok) | 880,000 | Indirect beneficial ownership via trustee manager role . |
| Total beneficial ownership | 4,850,000 | Represents 1.17% of outstanding shares (414,186,296) . |
- Ownership guidelines (directors): 3× annual cash retainer; five years to attain (non‑employee directors elected in 2023 have until 2028) .
- Hedging/pledging: Prohibited absent Audit Committee approval; Company anti‑hedging/anti‑pledging policy applies to directors .
Governance Assessment
- Alignment: Material personal/affiliated ownership of ~1.17% aligns incentives with shareholders; option‑heavy director equity mix further ties compensation to share price outcomes .
- Independence and oversight: Board deems him independent; independent Chair and fully independent key committees support effective oversight, though Torok had no committee assignment at appointment, limiting near‑term committee‑level influence until assignments are made post‑AGM .
- Engagement/attendance: Board met 10 times in 2024 with all then‑directors meeting attendance thresholds; Torok’s attendance will be assessable in 2025 reporting .
- Pay structure quality: Director pay offers cash/equity election and market‑median sizing; change‑in‑control full vesting is standard but can be shareholder‑sensitive; the increased option weighting is a positive alignment signal .
- Conflicts and related‑party risk: Company discloses no related‑party transactions; 8‑K affirms no Item 404(a) transactions for Torok on appointment; hedging/pledging restrictions mitigate alignment risks. Continued monitoring warranted given indirect holdings via entities he manages, although no pledges are disclosed .
RED FLAGS (monitor)
- No committee assignment at appointment (may be temporary; monitor post‑AGM committee placements) .
- Change‑in‑control acceleration for director equity (industry standard but can face investor scrutiny) .
Supportive Signals
- Significant beneficial ownership and option‑heavy director equity structure .
- Independent status within an independently led board framework .
- No related‑party transactions disclosed; deed of indemnity to be executed in standard form .
Employment & Contracts (Director)
- Appointment date: April 4, 2025; service through 2025 AGM; nominated for re‑election .
- Deed of indemnity: Company expects to enter into standard director deed of indemnity with Torok .
Director Compensation Structure Analysis
| Aspect | 2024–2025 Policy Detail | Implication |
|---|---|---|
| Cash retainer | $62.5k + committee/Chair fees; quarterly; share election available | Flexibility and potential for higher equity alignment via share elections . |
| Initial equity award | $262.5k (75% options/25% RSUs); staggered vesting | Strong price alignment; vesting supports retention . |
| Annual equity award | $175k (75% options/25% RSUs) | Sustained price alignment over tenure . |
| CIC treatment | Full vesting of director awards | Standard; monitor investor sentiment on CIC acceleration . |
Say‑on‑Pay & Shareholder Feedback (context)
- 2024 say‑on‑pay approval ~79.5% of votes cast; Board and Remuneration Committee expanded engagement and simplified incentive design, including heavier option weighting and clearer outcomes‑based goals (executive program context) .
Related‑Party Transactions
- None reported since Jan 1, 2024; Torok specifically not party to any Item 404(a) transactions per his 8‑K appointment disclosure .
Past Roles (detail table)
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| JEC Capital Partners, LLC | Co‑Founder & Managing Director | 2008–present | Investor/operator; capital markets, M&A, operations . |
| Integrated Dynamics Engineering (Aalberts Industries) | CFO | 2006–2009 | Led finance; sale to Aalberts . |
| PwC | Various | N/A | Financial services focus . |
External Roles (detail table)
| Company | Role | Tenure | Notes |
|---|---|---|---|
| Liberated Syndication, Inc. | Director | Dec 2022–present | Public company board . |
| Carisma Therapeutics Inc. | Director | Mar 2023–Oct 2024 | Former director . |
| Photon Control Inc. | Director | 2016–2018 | Former director . |
| Symbility Solutions Inc. | Director | 2015–2018 | Former director . |
| Various (general) | Committee contributions | N/A | Contributions across audit/comp/N&G/strategic/pricing committees (press release) . |
Equity Ownership (detail table)
| Category | Shares | % of Outstanding | Source/Notes |
|---|---|---|---|
| Direct | 970,000 | — | As of April 4, 2025 . |
| Indirect – JEC II Associates, LLC (manager: Torok) | 3,000,000 | — | Indirect via entity managed by Torok . |
| Indirect – The MOS Trust (trustee manager entity managed by Torok) | 880,000 | — | Indirect via trust arrangement . |
| Total | 4,850,000 | 1.17% (of 414,186,296) | Beneficial ownership table and footnote; outstanding share count as of Feb 28, 2025 . |
Notes on Policies Relevant to Alignment
- Director stock ownership guideline: 3× annual cash retainer; 5 years to comply (directors from 2023 cohort have until 2028) .
- Insider trading policy: Prohibits hedging and pledging absent Audit Committee approval; clawback policy in place for executives (governance backdrop) .